Publikationen in Zusammenarbeit mit Forschern von University of Sydney (27)

2023

  1. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883

  2. Ravulizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

    Annals of Neurology, Vol. 93, Núm. 6, pp. 1053-1068

  3. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

    Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644

2022

  1. Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in

    Frontiers in Immunology, Vol. 13

  2. Multiple sclerosis in the era of COVID-19: Disease course, DMTs and SARS-CoV2 vaccinations

    Current Opinion in Neurology, Vol. 35, Núm. 3, pp. 319-327

  3. Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide

    Frontiers in Immunology, Vol. 13

2021

  1. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus

    Journal of Neurology, Vol. 268, Núm. 11, pp. 3961-3968

  2. Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis

    Neurology, Vol. 96, Núm. 24, pp. E2989-E3002

2019

  1. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study

    Multiple Sclerosis and Related Disorders, Vol. 28, pp. 235-243

2017

  1. Contribution of different relapse phenotypes to disability in multiple sclerosis

    Multiple Sclerosis, Vol. 23, Núm. 2, pp. 266-276

  2. Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response

    Brain, Vol. 140, Núm. 9, pp. 2426-2443

2016

  1. Defining secondary progressive multiple sclerosis

    Brain, Vol. 139, Núm. 9, pp. 2395-2405

  2. Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 87, Núm. 12, pp. 1343-1349

  3. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: A cohort study

    The Lancet Neurology, Vol. 15, Núm. 6, pp. 574-584

2015

  1. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

    Multiple Sclerosis, Vol. 21, Núm. 9, pp. 1159-1171

  2. Comparative efficacy of switching to natalizumab in active multiple sclerosis

    Annals of Clinical and Translational Neurology, Vol. 2, Núm. 4, pp. 373-387

  3. Defining reliable disability outcomes in multiple sclerosis

    Brain, Vol. 138, Núm. 11, pp. 3287-3298

  4. Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS

    PLoS ONE, Vol. 10, Núm. 6

  5. Predictors of disability worsening in clinically isolated syndrome

    Annals of Clinical and Translational Neurology, Vol. 2, Núm. 5, pp. 479-491

  6. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

    Annals of Neurology, Vol. 77, Núm. 3, pp. 425-435